House Subcommittee Presses FDA On Flu Assays For Vaccine Preparedness
This article was originally published in The Gray Sheet
Executive Summary
FDA should be developing a well-defined regulatory process for introducing alternative assays for seasonal flu vaccines, to prevent mismatches between new flu strains and vaccines, a House oversight subcommittee said in a series of letters to health care agencies on March 9, questioning the agencies’ flu preparedness.